the aid library

LIST OPTIONS

Filter

7916

Risk assessment on yellow fever virus circulation in endemic countries

World Health Organization WHO (2014) C_WHO

Working document from an informal consultation of experts. A Protocol for risk assessment at the field level. The purpose of document is to provide guidance on the methodology to be used for assessing, at field level, the yellow fever virus circulation in areas at risk, and is primarily intended fo... more

Download (454)

View PDF (307)

Handbook for public health capacity-building at ground crossings and cross-border collaboration

World Health Organization WHO (2020) C_WHO

This handbook follows a comprehensive approach to health system strengthening at borders in order to support IHR national focal points and other national agencies in developing and implementing evidence-based action plans for IHR capacity development at ground crossings. The approach includes the mo... more

Download (303)

View PDF (335)

Standard operating procedures for surveillance of meningitis preparedness and response to epidemics in Africa

World Health Organization WHO (2018) C_WHO

Epidemic meningitis is a major public health challenge in the African 'meningitis belt', an area that extends from Senegal to Ethiopia with an estimated total population of 500 million. Since 2002, the World Health Organization (WHO), in collaboration with its collaborating centres for meningitis, h... more

Download (1126)

View PDF (1325)

A framework for malaria elimination

World Health Organization WHO (2017) C_WHO

The document provides guidance on the tools, activities and strategies required to achieve malaria elimination and prevent re-establishment of transmission in countries, regardless of where they lie across the spectrum of transmission intensity. It is intended to inform national malaria elimination ... more

Download (255)

View PDF (549)

Handbook For Integrated Vector Management

World Health Organization WHO (2012) C_WHO

The intention of this handbook on integrated vector management (IVM) is to provide guidance to the managers of vector-borne disease control programmes, including comparable officials in health and other sectors involved in vector-borne disease control. The target audience is managers and official... more

Download (1004)

View PDF (1706)

From Malaria Control to Malaria Elimination: A Manual for Elimination Sce- nario Planning

Justin Cohen, Deepika Kandula, Bruno Moonen et al. World Health Organization WHO (2014)

The elimination scenario planning (ESP) manual provides malaria-endemic countries with a comprehensive framework to assess different scenarios for moving towards this goal, depending on programme coverage and funding availability. It also helps countries set realistic timelines and provides essentia... more

Download (410)

View PDF (336)

Responding to communicable and noncommunicable diseases: progress report 2020-2022

World Health Organization WHO (2023) C_WHO

Significant progress has been made in the eradication of three priority diseases in the African Region, as a result of extensive collaboration between the Regional Office, WHO country offices and countries. For example, in August 2020, the region was certified free of wild poliovirus. In the area of... more

Download (134)

View PDF (110)

Manual for Stratifying Malaria Risk and the Elimination of Foci

Pan American Health Organization PAHO (2022) C_WHO

All malaria-endemic countries in the Region of the Americas have taken on the challenge to eliminate the disease and to put in place measures to orient their health programs and strategies in that direction. This manual explains how to implement measures to achieve malaria elimination and prevent it... more

Download (129)

View PDF (108)

Plan of Action for Malaria Elimination 2021-2025

Pan American Health Organization PAHO (2022) C_WHO

The Plan subscribes to the goals and pillars of the WHO Global Technical Strategy against Malaria 2016-2030 (GTS), while presenting key elements to address the specific challenges of the Region.

Download (76)

View PDF (61)

Community deployment of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine: a field guide

World Health Organization WHO (2024) C_WHO

The document outlines essential steps and provides guidance to countries on the adoption and deployment of c-IPTp so that it is integrated into the existing health system. It draws upon best practices and lessons learned from pilot implementation experiences in eight African countries and targets st... more

Download (65)

View PDF (65)

WHO guidelines for malaria - arabic version

World Health Organisation (WHO) (2024) C_WHO

The WHO guidelines for malaria bring together the Organization’s most up-to-date recommendations for malaria in one user-friendly and easy-to-navigate online platform. The WHO guidelines for malaria bring together the Organization’s most up-to-date recommendations for malaria in one user-frie... more

Download (30)

View PDF (22)

Technical consultation to assess evidence on community-based delivery of intermittent preventive treatment in pregnancy for malaria

World Health Organization WHO (2023) C_WHO

Report of a virtual meeting 21–23 June 2022

Download (47)

View PDF (56)

National Malaria Elimination Strategic Plan (NMESP) 2024–2028

National Malaria Elimination Programme (NMEP) Ghana Health Service - Ministry of Health, Ghana (2023) C2

The National Malaria Elimination Strategic Plan (NMESP) 2024–2028 of Ghana outlines the country’s roadmap to shift from malaria control to elimination. Despite major progress—like reducing malaria deaths from nearly 2,800 in 2012 to 151 in 2022—malaria remains a major public health challenge... more

Download (420)

View PDF (364)

International health regulations (‎2005)‎: state party self-assessment annual reporting tool, 2nd ed

World Health Organization WHO (2022) C_WHO

Second edition. AVailable in English, French, Spanish, Russian, Chinese and Portuguese

Download (404)

View PDF (477)

Medical Isolation Facilities in Outbreak Responses

Oxfam (2018) C1

Download (1659)

View PDF (2863)

WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health-care settings
recommended

World Health Organization (2016) C_WHO

Download (240)

View PDF (364)

Guidelines for Management of ST-Elevated Myocardial Infarction

Directorate General of Health Services Ministry of Health & Family Welfare Government of India (2022) CC

Myocardial infarctions are generally clinically classified into ST elevation MI (STEMI) and non-ST elevation MI (NSTEMI), based on changes in ECG. When blood flow to a part of the heart stops or the heart is injured and fails to receive enough oxygen required for its adequate functioning the conditi... more

Download (417)

View PDF (429)

Democratic Republic of Timor-Leste Ministry of Health - Comprehensive TB Guidelines for National Tuberculosis Program, V Edition

Government of Timor-Leste; World Health Organization (2023) CC

The Democratic Republic of Timor-Leste has the highest TB incidence rate in the South East Asian Region - 498 per 100,000, which is the seventh highest in the world. In Timor-Leste TB is the eighth most common cause of death. The salient observations are as follows: In 2018, 487 (12.5%) of the... more

Download (473)

View PDF (697)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health-care settings recommended

WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health-care settings
recommended